Get the Stockscreener App
4.93
0.00%
0.00
After Hours:
4.93
Acelyrin Inc stock is traded at $4.93, with a volume of 277.42K.
It is up +0.00% in the last 24 hours and up +3.14% over the past month.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
See More
Previous Close:
$4.93
Open:
$4.89
24h Volume:
277.42K
Relative Volume:
0.25
Market Cap:
$492.05M
Revenue:
-
Net Income/Loss:
$-299.80M
P/E Ratio:
-0.4067
EPS:
-12.1221
Net Cash Flow:
$-217.49M
1W Performance:
-0.20%
1M Performance:
+3.14%
6M Performance:
-26.96%
1Y Performance:
-51.52%
1-Day Range:
$4.7855
$5.09
1-Week Range:
$4.75
$5.12
52-Week Range:
$3.36
$10.71
Acelyrin Inc Stock (SLRN) Company Profile
Name
Acelyrin Inc
Sector
Industry
Phone
805-871-4300
Address
4149 LIBERTY CANYON RD., AGOURA HILLS
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Sep-13-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-05-23 | Initiated | H.C. Wainwright | Buy |
| May-30-23 | Initiated | Jefferies | Buy |
| May-30-23 | Initiated | Morgan Stanley | Overweight |
| May-30-23 | Initiated | Piper Sandler | Overweight |
| May-30-23 | Initiated | TD Cowen | Outperform |
View All
Acelyrin Inc Stock (SLRN) Latest News
Almitas Capital LLC Buys New Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Short Interest in Acelyrin, Inc. (NASDAQ:SLRN) Drops By 15.4% - MarketBeat
Piper Sandler maintains Overweight rating on Acelyrin shares - Investing.com
Piper Sandler maintains Overweight rating on Acelyrin shares - Investing.com India
Acelyrin Inc [SLRN] Director makes an insider sale of 1 shares worth $7.0. - Knox Daily
Top investors say Acelyrin Inc (SLRN) ticks everything they need - SETE News
Acelyrin Insider Sellers Miss The Bus As Stock Jumps 12% - Simply Wall St
Can Acelyrin Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Down 5.4% - MarketBeat
Acelyrin (NASDAQ:SLRN) Shares Down 5.4% - Defense World
How did Acelyrin Inc (SLRN) fare last session? - US Post News
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch (NASDAQ:SLRN) - Seeking Alpha
Acelyrin (NASDAQ:SLRN) Shares Gap Up to $4.60 - MarketBeat
Acelyrin stock spikes on upcoming presentation (NASDAQ:SLRN) - Seeking Alpha
Acelyrin announces positive results from Phase 3 trial of izokibep - TipRanks
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 - StockTitan
Acelyrin Inc (SLRN) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Acadian Asset Management LLC Makes New $590,000 Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
In the Green: Acelyrin Inc (SLRN) Closes at 4.31, Up/Down -8.30 from Previous Day - The Dwinnex
Results from Acelyrin Inc (SLRN) show risk - US Post News
SLRN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Los Angeles Capital Management LLC Takes $693,000 Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc - Yahoo Finance
Significant Acquisition by T. Rowe Price Investment Management i - GuruFocus.com
Acelyrin announces PoC data from Phase 1/2 trial of lonigutamab - TipRanks
ACELYRIN reports positive Phase 1/2 trial data for TED therapy - Investing.com Australia
ACELYRIN reports positive Phase 1/2 trial data for TED therapy - Investing.com
Acelyrin Inc (SLRN) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of - The Bakersfield Californian
Acelyrin, Inc. (NASDAQ:SLRN) Receives $10.83 Average Target Price from Analysts - MarketBeat
How does Acelyrin Inc (SLRN) change from a tortoise to a hare? - SETE News
Is it possible to buy Acelyrin Inc(SLRN) shares at a good price now? - US Post News
Acelyrin Inc (SLRN)’s Market Momentum: Closing Strong at 4.78, Down -0.62 - The Dwinnex
Company’s Banking Stock: Dissecting a 18.77% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Financial Metrics Unveiled: Acelyrin Inc (SLRN)’s Key Ratios in the Spotlight - The Dwinnex
Stocks of Acelyrin Inc (SLRN) are poised to climb above their peers - SETE News
Was there any good news for Acelyrin Inc (SLRN) stock in the last session? - US Post News
ACELYRIN, INC. to Participate in Upcoming Investor Conferences - StockTitan
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024 - MSN
Acelyrin (NASDAQ:SLRN) Price Target Cut to $6.00 by Analysts at Morgan Stanley - Defense World
California State Teachers Retirement System Has $49,000 Stock Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Morgan Stanley cuts Acelyrin stock target, holds equalweight on izokibep halt - Investing.com India
Acelyrin (NASDAQ:SLRN) PT Lowered to $6.00 at Morgan Stanley - MarketBeat
Morgan Stanley cuts Acelyrin stock target, holds equalweight on izokibep halt - Investing.com Canada
Closing Strong: Acelyrin Inc (SLRN) Ends at 4.13, Up 3.77 from Last Close - The Dwinnex
Morgan Stanley cuts Acelyrin stock target, holds equalweight on izokibep halt - Investing.com UK
20,703 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Acquired by Price T Rowe Associates Inc. MD - Defense World
Acelyrin (NASDAQ:SLRN) Stock Rating Lowered by HC Wainwright - Defense World
Brokerages Set Acelyrin, Inc. (NASDAQ:SLRN) Target Price at $12.00 - Defense World
Q3 2024 Earnings Forecast for Acelyrin, Inc. (NASDAQ:SLRN) Issued By HC Wainwright - MarketBeat
Q3 2024 Earnings Estimate for Acelyrin, Inc. (NASDAQ:SLRN) Issued By HC Wainwright - Defense World
Acelyrin Inc Stock (SLRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):